◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › A › ARDX

Ardelyx Inc (ARDX) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-09-18

Ardelyx Inc (ARDX) operates in the BIOTECHNOLOGY industry and is headquartered in Waltham, United States with about 489 employees. Its market capitalization is roughly $883 million. In the fiscal year ended 2025-12-31, ARDX reported $407M in revenue and ($62M) in net income.

Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.

Interactive charts & full statements → Open the ARDX valuation workbench →

ARDX Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31
Total Revenue	$451M	$407M	$334M	$124M	$52M	$10M	$8M	$5M	$3M	$42M	$24M	$24M	$32M	$29M	$5M
Gross Profit	$424M	$365M	$283M	$107M	$48M	$9M	$7M	$5M	$2M	$34M	$23M	$24M	$32M	$1M	$3M
Gross Margin %	94.0%	89.5%	84.9%	85.7%	92.1%	90.1%	98.1%	88.6%	82.1%	80.0%	94.6%	100.0%	100.0%	2.9%	64.7%
Operating Income (EBIT)	($35M)	($41M)	($28M)	($63M)	($64M)	($154M)	($91M)	($91M)	($91M)	($65M)	($113M)	($29M)	($2M)	($3M)	($9M)
Operating Margin %	-7.9%	-10.1%	-8.4%	-50.8%	-122.2%	-1528.6%	-1199.1%	-1728.1%	-3488.6%	-155.0%	-469.9%	-122.3%	-5.0%	-9.9%	-162.8%
Net Income	($56M)	($62M)	($39M)	($66M)	($67M)	($158M)	($94M)	($95M)	($91M)	($64M)	($112M)	($30M)	($3M)	($7M)	($10M)
Net Margin %	-12.3%	-15.1%	-11.7%	-53.1%	-128.8%	-1566.5%	-1245.7%	-1797.8%	-3502.0%	-153.2%	-467.8%	-123.3%	-10.2%	-22.7%	-180.9%
EBITDA	($24M)	($29M)	($17M)	($55M)	($61M)	($151M)	($85M)	($85M)	($85M)	($62M)	($112M)	($29M)	($1M)	($2M)	($8M)
Earnings Per Share (EPS)	$-0.23	$-0.26	$-0.17	$-0.30	$-0.42	$-1.52	$-1.05	$-1.47	$-1.62	$-1.36	$-2.80	$-1.29	$-0.31	$-0.49	$-0.73
Shares Outstanding (M)	248M	241M	235M	219M	159M	104M	90M	64M	56M	47M	40M	23M	10M	13M	13M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ARDX Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$121M	$94M	$125M	$110M	$98M	$74M	$116M	$98M
Gross Profit	$115M	$90M	$113M	$105M	$85M	$61M	$98M	$83M
Gross Margin %	95.2%	94.9%	90.6%	95.6%	86.7%	82.6%	84.3%	84.0%
Operating Income (EBIT)	($12M)	($33M)	$5M	$5M	($14M)	($36M)	$8M	$2M
Operating Margin %	-10.3%	-34.7%	4.1%	4.2%	-14.7%	-49.0%	7.0%	2.3%
Net Income	($17M)	($38M)	$0M	($1M)	($19M)	($41M)	$5M	($1M)
Net Margin %	-13.8%	-39.8%	-0.3%	-0.9%	-19.5%	-55.5%	4.0%	-0.8%
EBITDA	($10M)	($30M)	$8M	$8M	($12M)	($33M)	$11M	$5M
Earnings Per Share (EPS)	$-0.07	$-0.15	$-0.00	$-0.00	$-0.08	$-0.17	$0.02	$-0.00
Shares Outstanding (M)	248M	246M	244M	242M	240M	239M	244M	236M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ARDX Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31
Cash from Operations (CFO)	($17M)	($42M)	($45M)	($90M)	($70M)	($153M)	($81M)	($76M)	($70M)	($65M)	($93M)	($72M)	$13M	$2M	$22M
Capital Expenditures (CapEx)	$1M	$1M	$1M	$0M	$0M	$2M	$0M	$0M	$0M	$2M	$5M	$3M	$2M	$0M	$0M
Free Cash Flow (FCF)	($18M)	($44M)	($46M)	($90M)	($70M)	($154M)	($82M)	($77M)	($71M)	($68M)	($97M)	($75M)	$12M	$2M	$22M
FCF Margin %	-4.0%	-10.8%	-13.7%	-72.4%	-134.4%	-1529.3%	-1079.9%	-1454.4%	-2707.5%	-160.8%	-405.4%	-313.4%	36.5%	5.3%	403.9%
Dividends Paid	—	—	—	$26M	—	$0M	—	—	—	$0M	$0M	$0M	$0M	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ARDX Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	($6M)	($32M)	$21M	$0M	($25M)	($38M)	$10M	$1M
Capital Expenditures (CapEx)	$0M	$0M	$0M	$0M	$1M	$0M	$1M	$0M
Free Cash Flow (FCF)	($6M)	($32M)	$21M	$0M	($26M)	($39M)	$9M	$0M
FCF Margin %	-5.3%	-34.2%	16.4%	0.2%	-26.6%	-52.3%	7.9%	0.4%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ARDX Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31
Total Assets	$576M	$502M	$436M	$298M	$190M	$150M	$202M	$260M	$183M	$158M	$213M	$117M	$113M	$43M	$38M
Cash & Cash Equivalents	$97M	$68M	$65M	$21M	$96M	$72M	$91M	$181M	$79M	$75M	$75M	$107M	$107M	$34M	$33M
Total Liabilities	$427M	$335M	$262M	$131M	$92M	$67M	$75M	$73M	$68M	$19M	$20M	$8M	$53M	$50M	$39M
Total Debt (Short + Long-Term)	$253M	$204M	$152M	$54M	$31M	$36M	$55M	$55M	$50M	$0M	$0M	$0M	$16M	$0M	$0M
Total Shareholders' Equity	$149M	$167M	$173M	$167M	$98M	$83M	$126M	$187M	$116M	$139M	$193M	$109M	$61M	($7M)	($1M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ARDX viewer.

Other Companies in BIOTECHNOLOGY

HELP · Cybin Inc. Common Stock — $904 million
IMMX · Immix Biopharma Inc — $894 million
FTH · Faeth Therapeutics, Inc. — $891 million
TBPH · Theravance Biopharma Inc — $884 million
RIGL · Rigel Pharmaceuticals Inc — $871 million
OLMA · Olema Pharmaceuticals Inc — $859 million
WVE · Wave Life Sciences Ltd — $857 million
CADL · Candel Therapeutics Inc — $830 million

← ARDT All “A” companies ARE →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.